June 5, 2022 SanaCurrents Portfolio Update: APLS files NDA, IMUX UC drug falters in phase II topline, plus VERA and ACET This content is for members only
March 19, 2022 SanaCurrents on Apellis’ (APLS) clinical rebound to treat rare form of blindness This content is for members only
January 7, 2020 Portfolio Update: Apellis Rises While Agile Gains Traction Ahead of PDUFA This content is for members only